Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9932801 | 0.83 | ALDH1A1 (0.36) | SMN1; SMN2CYP2C19HIF1ACYP2C9MT-CO2 | |
| SCHEMBL16283604 | 0.69 | MAPT (0.41) | SMN1; SMN2CYP2C19HIF1ACYP2C9MT-CO2 | |
| SCHEMBL28859583 | 0.68 | LMNA (0.35) | SMN1; SMN2CYP2C19CYP2C9 | |
| SCHEMBL13838039 | 0.67 | CTRC (0.45) | PLAUMAPTKMT2A | |
| SCHEMBL4248469 | 0.67 | NFKB1 (0.38) | CYP2C19HIF1ACYP2C9MT-CO2ALOX5 | |
| SCHEMBL11625994 | 0.67 | BRD4 (0.41) | CYP2C19CYP2C9 | |
| SCHEMBL9669676 | 0.67 | CYP2C19 (0.39) | SMN1; SMN2CYP2C19HIF1ACYP2C9MT-CO2 | |
| SCHEMBL21091813 | 0.66 | ALDH1A1 (0.34) | MAPTKMT2A | |
| SCHEMBL11467541 | 0.63 | MCL1 (0.44) | CYP2C19CYP2C9MT-CO2ALOX5MAPT | |
| SCHEMBL8398128 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765978-B2 | Method of making indeno-fused naphthol materials | TRANSITIONS OPTICAL, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120157696-A1 | METHOD OF MAKING INDENO-FUSED NAPHTHOL MATERIALS | TRANSITIONS OPTICAL, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157696-A1 | METHOD OF MAKING INDENO-FUSED NAPHTHOL MATERIALS | NQO1, IDH3A, IDH2 | PLAU 3990/4885SMN1; SMN2 4107/4885CYP2C19 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.